|
Fusion gene ID: 37771 |
FusionGeneSummary for TET2_LANCL1 |
Fusion gene summary |
Fusion gene information | Fusion gene name: TET2_LANCL1 | Fusion gene ID: 37771 | Hgene | Tgene | Gene symbol | TET2 | LANCL1 | Gene ID | 54790 | 10314 |
Gene name | tet methylcytosine dioxygenase 2 | LanC like 1 | |
Synonyms | KIAA1546|MDS | GPR69A|p40 | |
Cytomap | 4q24 | 2q34 | |
Type of gene | protein-coding | protein-coding | |
Description | methylcytosine dioxygenase TET2probable methylcytosine dioxygenase TET2tet oncogene family member 2 | lanC-like protein 140 kDa erythrocyte membrane proteinG protein-coupled receptor 69ALanC (bacterial lantibiotic synthetase component C)-like 1LanC (bacterial lantibiotic synthetase component)LanC lantibiotic synthetase component C-like 1 | |
Modification date | 20180523 | 20180523 | |
UniProtAcc | Q6N021 | O43813 | |
Ensembl transtripts involved in fusion gene | ENST00000545826, ENST00000513237, ENST00000540549, ENST00000380013, ENST00000305737, ENST00000394764, ENST00000504042, ENST00000413648, | ENST00000443314, ENST00000441020, ENST00000450366, ENST00000233714, ENST00000431941, | |
Fusion gene scores | * DoF score | 6 X 4 X 6=144 | 5 X 3 X 5=75 |
# samples | 7 | 5 | |
** MAII score | log2(7/144*10)=-1.04064198449735 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(5/75*10)=-0.584962500721156 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: TET2 [Title/Abstract] AND LANCL1 [Title/Abstract] AND fusion [Title/Abstract] | ||
Functional or gene categories assigned by FusionGDB annotation |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | TET2 | GO:0006211 | 5-methylcytosine catabolic process | 24315485 |
Hgene | TET2 | GO:0006493 | protein O-linked glycosylation | 23222540 |
Hgene | TET2 | GO:0080111 | DNA demethylation | 24315485 |
Tgene | LANCL1 | GO:0007186 | G-protein coupled receptor signaling pathway | 10944443 |
Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
TCGA | LD | BRCA | TCGA-A2-A1FV-01A | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
* LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
3UTR-5UTR | ENST00000545826 | ENST00000443314 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
3UTR-5UTR | ENST00000545826 | ENST00000441020 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
3UTR-5UTR | ENST00000545826 | ENST00000450366 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
3UTR-5UTR | ENST00000545826 | ENST00000233714 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
3UTR-5UTR | ENST00000545826 | ENST00000431941 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
5CDS-5UTR | ENST00000513237 | ENST00000443314 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
5CDS-5UTR | ENST00000513237 | ENST00000441020 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
5CDS-5UTR | ENST00000513237 | ENST00000450366 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
5CDS-5UTR | ENST00000513237 | ENST00000233714 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
5CDS-5UTR | ENST00000513237 | ENST00000431941 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
5CDS-5UTR | ENST00000540549 | ENST00000443314 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
5CDS-5UTR | ENST00000540549 | ENST00000441020 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
5CDS-5UTR | ENST00000540549 | ENST00000450366 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
5CDS-5UTR | ENST00000540549 | ENST00000233714 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
5CDS-5UTR | ENST00000540549 | ENST00000431941 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
5CDS-5UTR | ENST00000380013 | ENST00000443314 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
5CDS-5UTR | ENST00000380013 | ENST00000441020 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
5CDS-5UTR | ENST00000380013 | ENST00000450366 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
5CDS-5UTR | ENST00000380013 | ENST00000233714 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
5CDS-5UTR | ENST00000380013 | ENST00000431941 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
intron-5UTR | ENST00000305737 | ENST00000443314 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
intron-5UTR | ENST00000305737 | ENST00000441020 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
intron-5UTR | ENST00000305737 | ENST00000450366 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
intron-5UTR | ENST00000305737 | ENST00000233714 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
intron-5UTR | ENST00000305737 | ENST00000431941 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
intron-5UTR | ENST00000394764 | ENST00000443314 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
intron-5UTR | ENST00000394764 | ENST00000441020 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
intron-5UTR | ENST00000394764 | ENST00000450366 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
intron-5UTR | ENST00000394764 | ENST00000233714 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
intron-5UTR | ENST00000394764 | ENST00000431941 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
intron-5UTR | ENST00000504042 | ENST00000443314 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
intron-5UTR | ENST00000504042 | ENST00000441020 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
intron-5UTR | ENST00000504042 | ENST00000450366 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
intron-5UTR | ENST00000504042 | ENST00000233714 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
intron-5UTR | ENST00000504042 | ENST00000431941 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
intron-5UTR | ENST00000413648 | ENST00000443314 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
intron-5UTR | ENST00000413648 | ENST00000441020 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
intron-5UTR | ENST00000413648 | ENST00000450366 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
intron-5UTR | ENST00000413648 | ENST00000233714 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
intron-5UTR | ENST00000413648 | ENST00000431941 | TET2 | chr4 | 106164935 | + | LANCL1 | chr2 | 211341136 | - |
Top |
FusionProtFeatures for TET2_LANCL1 |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
TET2 | LANCL1 |
Dioxygenase that catalyzes the conversion of themodified genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) and plays a key role in active DNAdemethylation. Has a preference for 5-hydroxymethylcytosine in CpGmotifs. Also mediates subsequent conversion of 5hmC into 5-formylcytosine (5fC), and conversion of 5fC to 5-carboxylcytosine(5caC). Conversion of 5mC into 5hmC, 5fC and 5caC probablyconstitutes the first step in cytosine demethylation. Methylationat the C5 position of cytosine bases is an epigenetic modificationof the mammalian genome which plays an important role intranscriptional regulation. In addition to its role in DNAdemethylation, also involved in the recruitment of the O-GlcNActransferase OGT to CpG-rich transcription start sites of activegenes, thereby promoting histone H2B GlcNAcylation by OGT.{ECO:0000269|PubMed:19483684, ECO:0000269|PubMed:21057493,ECO:0000269|PubMed:21817016, ECO:0000269|PubMed:23222540,ECO:0000269|PubMed:23353889, ECO:0000269|PubMed:24315485}. | May play a role in EPS8 signaling. Binds glutathione.{ECO:0000269|PubMed:19528316}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for TET2_LANCL1 |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
* Fusion amino acid sequences. |
* Fusion transcript sequences (only coding sequence (CDS) region). |
* Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for TET2_LANCL1 |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
TET2 | TBC1D4, TCF3, PAN2, OGT, VPRBP, DDB1, EBF1, NONO, SEMG1 | LANCL1 | SIRT1, CUL3, SERPINH1, VHL, ERG, EGFR, ALDH16A1, DERA, TBC1D9, TBC1D9B, FIGN, MYO7A, IPP, OCIAD1, UBN2, NTRK1, MCM2, MCM5, CDC73, NR3C1, TRIM25 |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for TET2_LANCL1 |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for TET2_LANCL1 |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | TET2 | C0079774 | Peripheral T-Cell Lymphoma | 2 | CTD_human |
Hgene | TET2 | C0007134 | Renal Cell Carcinoma | 1 | CTD_human |
Hgene | TET2 | C0020981 | Angioimmunoblastic Lymphadenopathy | 1 | CTD_human |
Hgene | TET2 | C0023487 | Acute Promyelocytic Leukemia | 1 | CTD_human |
Hgene | TET2 | C0027643 | Neoplasm Recurrence, Local | 1 | CTD_human |
Hgene | TET2 | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
Hgene | TET2 | C0036920 | Sezary Syndrome | 1 | CTD_human |
Hgene | TET2 | C3463824 | MYELODYSPLASTIC SYNDROME | 1 | CTD_human;HPO |